Rimonabant and Regeneron Pharmaceuticals' injectable Axokine were both briefly discussed, as both have recently completed last-stage testing, Axokine helped patients lose 3.5 kg more than placebo, said Dr.
One of those drugs, Axokine, recently received fast-track approval status from the Food and Drug Administration--a first for an obesity drug.
At least two are in phase III, placebo-controlled trials: Axokine, or ciliary neurotrophic factor (Regeneron Pharmaceuticals), and Rimonabant, a cannabinoid receptor agonist (Sanofi-Sythelabo).
Axokine, the drug now seen as having the best chance of reaching the market first, was found serendipitously Seeking to develop drugs for neurologic diseases, Regeneron identified ciliary neurotrophic factor as a possible agent and tested it in patients with amyotrophic lateral sclerosis.
Unlike Axokine, which is given daily by subcutaneous injection, Rimonabant is an oral agent.